ONCAlert | 2018 SGO Annual Meeting on Women’s Cancer

Biosimilars MORE >>

A marketing authorization for ABP 980, a biosimilar to trastuzumab (Herceptin), has been issued a positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.